[
    [
        {
            "time": "",
            "original_text": "3年大涨7倍！遭高瓴减持后，千亿医药巨头赴港IPO 减持股份",
            "features": {
                "keywords": [
                    "高瓴减持",
                    "医药巨头",
                    "赴港IPO",
                    "减持股份"
                ],
                "sentiment_score": -0.6,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "3年大涨7倍！遭高瓴减持后，千亿医药巨头赴港IPO 减持股份",
                "Correlation": 9,
                "Sentiment": 5,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 7,
                "Market_Scope": 5,
                "Time_Proximity": 7,
                "Headline_Structure": 9,
                "Source_Recency": 8
            }
        },
        {
            "time": "",
            "original_text": "凯莱英医药通过聆讯：年营收31亿 在A股市值已超千亿",
            "features": {
                "keywords": [
                    "凯莱英",
                    "医药",
                    "聆讯",
                    "市值超千亿"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "凯莱英医药通过聆讯：年营收31亿 在A股市值已超千亿",
                "Correlation": 10,
                "Sentiment": 8,
                "Importance": 9,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 9,
                "Market_Scope": 4,
                "Time_Proximity": 8,
                "Headline_Structure": 8,
                "Source_Recency": 9
            }
        },
        {
            "time": "",
            "original_text": "国君固收天津泰达控股债券投资价值深度分析：稳如“泰”山，收益必“达”",
            "features": {
                "keywords": [
                    "国君固收",
                    "泰达控股",
                    "债券投资",
                    "收益"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "债券"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "国君固收天津泰达控股债券投资价值深度分析：稳如“泰”山，收益必“达”",
                "Correlation": 3,
                "Sentiment": 6,
                "Importance": 5,
                "Impact": 4,
                "Duration": 5,
                "Entity_Density": 4,
                "Market_Scope": 3,
                "Time_Proximity": 6,
                "Headline_Structure": 7,
                "Source_Recency": 7
            }
        },
        {
            "time": "",
            "original_text": "专访勃林格殷格翰张维：中国CMO业务飞速扩展 多款新药受益于早期临床的全球同步",
            "features": {
                "keywords": [
                    "勃林格殷格翰",
                    "CMO业务",
                    "新药",
                    "全球同步"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "专访勃林格殷格翰张维：中国CMO业务飞速扩展 多款新药受益于早期临床的全球同步",
                "Correlation": 6,
                "Sentiment": 7,
                "Importance": 6,
                "Impact": 5,
                "Duration": 6,
                "Entity_Density": 5,
                "Market_Scope": 7,
                "Time_Proximity": 6,
                "Headline_Structure": 6,
                "Source_Recency": 6
            }
        },
        {
            "time": "",
            "original_text": "一周IPO观察：网易云、微博卫龙、凯莱英通过港交所聆讯；能源EaaS公司递交招股书",
            "features": {
                "keywords": [
                    "IPO",
                    "凯莱英",
                    "聆讯",
                    "网易云",
                    "微博卫龙",
                    "能源EaaS"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "科技",
                    "医药",
                    "能源"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "一周IPO观察：网易云、微博卫龙、凯莱英通过港交所聆讯；能源EaaS公司递交招股书",
                "Correlation": 8,
                "Sentiment": 6,
                "Importance": 7,
                "Impact": 6,
                "Duration": 5,
                "Entity_Density": 8,
                "Market_Scope": 8,
                "Time_Proximity": 7,
                "Headline_Structure": 7,
                "Source_Recency": 7
            }
        },
        {
            "time": "",
            "original_text": "医疗健康：医保谈判结束 医药板块有所回暖",
            "features": {
                "keywords": [
                    "医疗健康",
                    "医保谈判",
                    "医药板块",
                    "回暖"
                ],
                "sentiment_score": 0.6,
                "policy_related": "true",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "医疗健康：医保谈判结束 医药板块有所回暖",
                "Correlation": 7,
                "Sentiment": 7,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 6,
                "Market_Scope": 9,
                "Time_Proximity": 8,
                "Headline_Structure": 6,
                "Source_Recency": 8
            }
        },
        {
            "time": "",
            "original_text": "追高加仓凯莱英（002821.SZ），顶级医药基金经理为何看好？",
            "features": {
                "keywords": [
                    "凯莱英",
                    "追高加仓",
                    "医药基金",
                    "经理看好"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "追高加仓凯莱英（002821.SZ），顶级医药基金经理为何看好？",
                "Correlation": 10,
                "Sentiment": 8,
                "Importance": 7,
                "Impact": 8,
                "Duration": 6,
                "Entity_Density": 10,
                "Market_Scope": 4,
                "Time_Proximity": 7,
                "Headline_Structure": 9,
                "Source_Recency": 7
            }
        },
        {
            "time": "",
            "original_text": "凯莱英(002821)签订重大合同，业绩显著提速可期",
            "features": {
                "keywords": [
                    "凯莱英",
                    "重大合同",
                    "业绩提速"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "凯莱英(002821)签订重大合同，业绩显著提速可期",
                "Correlation": 10,
                "Sentiment": 9,
                "Importance": 10,
                "Impact": 9,
                "Duration": 8,
                "Entity_Density": 10,
                "Market_Scope": 4,
                "Time_Proximity": 9,
                "Headline_Structure": 8,
                "Source_Recency": 9
            }
        }
    ]
]